On April 22, AstraZeneca announced that the long-acting C5 complement inhibitor Ultomiris (English trade name: Ultomiris, generic name: reslizumab injection) was officially approved in China for use in combination with conventional treatment drugs to treat adult generalized myasthenia gravis (gMG) patients with positive anti-acetylcholine receptor (AChR) antibodies. Currently, reslizumab has been approved for the treatment of adult gMG patients with positive anti-AChR antibodies in the United States, the European Union, Japan and other countries and regions, and has been approved for multiple indications in many countries and regions around the world.